Independent analysis puts a HJ dulaglutide lot at 98.7%, against 96.2% on the certificate
The report states the gradient, the wavelength and the integration threshold, which is more than most.
The archive — 2025
Page 34 of 68 of this archive, newest first.
The dose that got you here and the dose that keeps you here
Every withdrawal trial compared full dose against nothing. The clinically interesting comparison — full dose against a reduced one — has not been randomised.
What changed at QST in July, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
What the new Nigeria guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
From the floor in Chengdu: 20 posters, one theme
Reported from the sessions, and from the two hours afterwards.
South Korea health authority warns on falsified tirzepatide pens
Reported from the analysis, not from a warning notice.
The certificate of analysis, line by line
The purity figure is the least informative line on a well-constructed certificate and the only line most buyers read.
The imaging substudy is an afterthought in the protocol and the centrepiece of the debate
The trials measured mass. Nobody measured whether the participants got weaker.
Hong Kong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Ireland pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The relabeller trading as Vantris Bio enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
PeptideMeter result on a Hong Kong mazdutide lot lands 2.6 points below the supplier’s figure
The result is unremarkable. What the report omits is not.
Escalating onto a rising curve
What the published pharmacokinetics permit, what the labels state, and where the two diverge.
Percentage of loss, absolute kilograms, and the sleight of hand between them
What was pre-specified, what was exploratory, and what was calculated afterwards by people who did not run the trial.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
A shortage listing ends. 9 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Sweden health authority warns on falsified exenatide pens
Reported from the analysis, not from a warning notice.
The mechanism behind the mechanism
The receptor populations that produce satiety and the ones that produce nausea overlap substantially. That is why the ceiling of this drug class is where it is, and it is…
Why a dead-clean sterile filter can pass pyrogen straight through
Bacterial endotoxin is a heat-stable lipopolysaccharide from the outer membrane of Gram-negative organisms. It survives sterilisation, passes a sterilising filter, and is…
From the floor in Shanghai: 12 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
SURMOUNT-4 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
What a diode array adds, and why the certificate never shows it
A diode-array detector records the whole spectrum at every time point and can confirm that a peak is spectrally homogeneous. Almost nobody prints that information.
Which results should be repeated before they are investigated
What the pivotal programmes measured and how often, which is a more defensible template than most published monitoring schedules.
Electrospray, MALDI, and the choice that shapes every spectrum after it
The two ionisation techniques in general use produce different charge distributions, different adducts and different failure modes. Certificates almost never say which was…
The slide that was not in the abstract
Reported from the sessions, and from the two hours afterwards.
Switzerland pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Zhuhai export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Independent analysis puts a FGP retatrutide lot at 97.1%, against 95.4% on the certificate
The result is unremarkable. What the report omits is not.